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PPAR-d in Abca12/ keratinocytes
(Supplementary Figure S1 online). From
our studies and the literature (Di-Poi
et al., 2002), PPAR-d has been shown to
have at least an anti-apoptotic role in
Abca12/ keratinocytes; however, it
remains unclear whether the upregula-
tion of PPAR-d is in response to apoptosis
or decreased ABCA12 expression.
Furthermore, we have measured the
mRNA expression levels of other nucle-
ar hormone receptors, including PPAR-
a, PPAR-g, retinoic acid receptor-a,
liver X receptor-a, liver X receptor-b,
RXR-a, and RXR-g (Applied Biosys-
tems). The mRNA level of RXR-a from
Abca12/ epidermis was shown to be
significantly higher than that from wild-
type epidermis (Supplementary Figure
S1 online). The interaction between the
upregulation of RXR-a and AKT activa-
tion in keratinocytes has not been
reported. However, Wang et al. (2011)
reported that RXR-a ablation in the
epidermis enhances UV-induced apop-
tosis, which suggests that RXR-a has an
anti-apoptotic function in keratino-
cytes. Thus, upregulation of RXR-a
may also have an anti-apoptotic func-
tion in Abca12/ keratinocytes.
In conclusion, the present data
suggest that keratinocyte apoptosis is
involved in the pathomechanisms of HI
and that the AKT signaling pathway
helps Abca12/ keratinocytes to sur-
vive during the keratinization process.
In light of this, activation of the AKT
signal pathway may be to our knowl-
edge, previously unreported strategy
for treating keratinization disorders,
including ichthyosis.
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TO THE EDITOR
Health-related quality of life (HRQL) is
commonly assessed by means of standar-
dized questionnaires and expressed in
domain and overall HRQL scores. An
important challenge is to interpret these
scores correctly. What does a given score
really mean? Although there is no standard
approach, several methods exist to facil-
itate the interpretation of HRQL scores.
In a recently published study
(Prinsen et al., 2010), we identified
See related commentary on pg 1790
Abbreviation: HRQL, health-related quality of life
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clinically meaningful domain and over-
all cutoff scores for the Skindex-29
(Chren et al., 1997a, b) by using an
anchor-based method (Guyatt et al.,
2002). We related patient responses on
the Skindex-29 to anchor questions,
and we established cutoff scores by
using receiver-operating characteristic
analysis. As a result, we were able to
determine cutoffs for severely impaired
HRQL (Table 1).
In a commentary on the interpre-
tation of HRQL scores, Chren (2010)
stressed the relevance of Skindex-29
cutoff scores for mild and moderate
degrees of effect in addition to the
scores we presented for a severe degree
of effect. In this letter, we will provide
these additional cutoff scores.
We analyzed the data of our sample
of 322 patients to identify optimal
cutoff scores. Again, the Skindex-29
domain scores, and the overall score,
were related to three types of patient-
based anchors: (i) four global questions
on the impact of disease on HRQL;
(ii) a question on disease severity as
perceived by the patient; and (iii) the
results on the 12-item General Health
Questionnaire, a standardized instru-
ment to measure psychiatric morbidity.
For complete methods, we refer to the
original article (Prinsen et al., 2010).
The four global questions relating
to the impact of disease on HRQL
showed the highest correlation with
the domain and overall scores of the
Skindex-29 (range 0.54–0.79). Cutoff
scores associated with these anchors
also showed the highest accuracy, as
measured by the area under the curve
receiver-operating characteristic statis-
tic for mildly impaired HRQL (range
0.76–0.91) as well as for moderately
impaired HRQL (range 0.75–0.91). On
the basis of the results of these ana-
lyses, the optimal and most accurate
Skindex-29 cutoff scores for mildly and
moderately impaired HRQL could be
determined (Table 1).
The relatively similar cutoffs of X39
and X42 points for mildly and moder-
ately impaired HRQL, respectively, on
the symptom domain, result from the
lower correlation of that particular
anchor question with the corresponding
Skindex-29 domain score (r¼0.54).
This is also visible in the lower accu-
racy of the symptom domain and,
thereby, the lower discriminating
capacity between patients who per-
ceive mildly or moderately impaired
HRQL (area under the curve¼0.76
and 0.75, respectively). From an
analytical point of view, there is no
apparent explanation for this lower
correlation. We assume that patients
experienced a difference between the
meanings of ‘‘symptoms’’ as worded in
the anchor question and ‘‘symptoms’’
as worded in the seven questions
representing the symptoms domain of
the Skindex-29.
The presented Skindex-29 cutoff
scores for mildly, moderately, and
severely impaired HRQL are generally
higher than those presented in a study
by Nijsten et al. (2009), who used a
distribution-based method. In our
anchor-based study, the Skindex-29
cutoff scores were determined by
patients’ assessments on their HRQL,
whereas Nijsten et al. (2009) capita-
lized on the distribution of HRQL levels
in the sample. Cutoff scores established
by anchor-based methods depend on
the particular anchor questions and
their wording, but they are less depen-
dent on the distribution of HRQL
levels in the sample. As patients are
grouped by their scores on anchor
questions (i.e., mild, moderate, and
severe impairment), the obtained cutoff
scores are likely to show invariance
across samples. This is one of the
reasons for the popularity of anchor-
based methods in HRQL research, parti-
cularly in determining minimal impor-
tant differences and/or change in scores
on a HRQL instrument.
By providing these additional cutoff
scores, we hope to contribute to a
meaningful interpretation of HRQL
scores. To facilitate the application of
the identified cutoff scores in clinical
practice, it might be helpful, as a rule of
thumb or memory aid, to round off the
cutoffs for mild, moderate, and severe
impairment to X20, X30, and X40
points, respectively, for the domain and
overall scores, with the exception of the
symptoms domain.
As expressed in our original study,
we recommend further research on the
generalizability and, thereby, on the
robustness of the cutoff scores of
the Skindex-29.
Table 1. Skindex-291 cutoff scores for mildly, moderately, and severely impaired HRQL
Impact of disease on HRQL for Skindex-29 domain and
Skindex-29 cutoff scores AUC3
overall scores2 Correlation Mild Moderate Severe4 Mild Moderate Severe4
Symptoms (r=0.54) 39 42 52 0.76 0.75 0.83
Emotions (r=0.73) 24 35 39 0.87 0.86 0.88
Functioning (r=0.79) 21 32 37 0.91 0.91 0.91
Overall (r=0.75) 25 32 44 0.85 0.90 0.90
Abbreviations: AUC, area under the curve; HRQL, health-related quality of life.
1The domain scores and the overall score are expressed on a 100-point scale, with higher scores indicating a lower level of quality of life.
2The number of patients in each severity category varies, as it largely depends on the required number of responses to the Skindex-29 domains. The number
of patients with mildly impaired HRQL ranged from 144–195; the number of patients with moderately impaired HRQL ranged from 73–104; and the number
of patients with severely impaired HRQL ranged from 49–74.
3AUC: 0.50 indicates chance categorization and 1.00 indicates perfect categorization of a given Skindex-29 score to correctly classify mild, moderate, or
severe impairment of HRQL.
4Cutoff scores and AUC coefficients for severely impaired HRQL as presented in the original article (Prinsen et al., 2010).
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TO THE EDITOR
Netherton syndrome (NS) is a severe
autosomal recessive skin disorder
caused by mutations in serine protease
inhibitor Kazal-type 5 (SPINK5), which
encodes the lymphoepithelial Kazal-
type-related inhibitor (LEKTI) (Chavanas
et al., 2000). Lack of LEKTI causes
stratum corneum detachment second-
ary to the hyperactivity of epidermal
proteases, which leads to skin barrier
defect, thus facilitating allergen pene-
tration and contributing to atopy in NS.
Affected individuals have chronic and
severe skin inflammation and allergic
manifestations, including atopic derma-
titis–like lesions and elevated serum IgE
levels. Recent studies have shown
that thymic stromal lymphopoietin
(TSLP) and tumor necrosis factor-alpha
(TNF-a) are overexpressed in the LEKTI-
deficient epidermis of NS patients and
SPINK5-null mice (Briot et al., 2009).
This is due to unrestricted activity of
epidermal proteases, including kallik-
rein 5, which activates PAR2 signaling
in keratinocytes, leading to NF-kB
activation and TSLP expression (Briot
et al., 2010). TSLP is produced
by keratinocytes as well as airway
epithelial cells and is necessary and
sufficient for inducing atopic response
in mice (Yoo et al., 2005; Li al., 2006).
It regulates innate immunity and po-
larizes T cells toward a T helper type 2
(Th2) phenotype through the condi-
tioning of antigen-presenting cells
(Soumelis et al., 2002; Soumelis and
Liu, 2004). TNF-a and IL-1 (Lee and
Ziegler, 2007) induce expression of
TSLP, which can synergize with these
pro-inflammatory cytokines to amplify
pro-Th2 cytokine secretion by activated
mast cells (Allakhverdi et al., 2007).
These data suggest that a therapeutic
approach targeting these key molecules
could reduce skin inflammation in NS.
The data and procedures reported in
this article were in accordance with
the institutional ethical requirements of
the University Hospital of Geneva,
Switzerland. The study was conducted
in adherence with the Declaration of
Helsinki Principles. Written informed
consent was obtained from the patient,
a 25-year-old woman who consulted
for an extensive pruritic dermatitis that
had been evolving since birth and was
associated with ichthyosis, asthma,
food allergies, and high levels of IgE
(3, 660 kU l1). The recurrent, severe
inflammatory flares were unresponsive
to systemic dapsone, topical steroids,
tacrolimus, and pimecrolimus. The pre-
sence of diffuse xerosis, a pattern of
ichthyosis circumflexa (Figure 1a), and
outbreaks of severe vesicular and pust-
ular lesions led to the diagnosis of NS,
which was supported by the absence of
epidermal LEKTI detection (Figure 1c,
d). SPINK5 molecular analysis identified
a homozygous mutation leading to a
premature termination codon in exon
12, thus confirming the diagnosis of NS.
Histological analysis of skin sections
revealed an acanthotic and spongiotic
epidermis with subcorneal accumu-
lation of neutrophils (Figure 1e).
A lymphohistiocytic infiltrate with neu-
trophils and eosinophils was present in
the superficial dermis, whereas the
density of mast cells was similar to that
in normal skin. Because TNF-a is
critical for neutrophil skin emigration
(Groves et al., 1995) and skin mast cell
Abbreviations: LEKT1, lymphoepithelial Kazal-type-related inhibitor; NS, Netherton syndrome; SPINK5,
serine protease inhibitor Kazal-type 5; Th2, T helper type 2; TNF-a, tumor necrosis factor-a; TSLP, thymic
stromal lymphopoietin
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